Mirta Isabel Acuña Ávila
Lider del Programa de Uso racional de Antimicrobianos
HOSPITAL ROBERTO DEL RÍO
Santiago, Chile
Infecciones respiratorias virales; bacterianas; Biologa molecular en el diagnstico de infecciones; Interccn Bacteria-Hospedero; Diagnstico molecular; Neutropenia Febril / infecciones Fngicas Invasoras; Reactantes de fase aguda; Infecciones intrahospitalarias; Consumo de antibiticos
-
Medica Cirujana, UNIVERSIDAD DE CONCEPCION. Chile, 1994
-
Especialista en Pediatría, UNIVERSIDAD DE CHILE. Chile, 2000
-
Especialista en Infectología pediátrica, UNIVERSIDAD DE CHILE. Chile, 2007
-
salud publica, UNIVERSIDAD DE CHILE. Chile, 2023
-
Profesora asociada Part Time
UNIVERSIDAD DE CHILE
Medicina
Santiago, Chile
2000 - At present
-
Lider Programa de Uso Racional de Antimicrobianos Full Time
Hospital Roberto del Río
Santiago, Chile
2000 - At present
-
Directora del Hospital Other
Hospital Roberto del Río
Santiago, Chile
2018 - 2019
-
subdirectora del hospital Full Time
Hospital Roberto del Río
Santiago, Chile
2017 - 2018
-
Mejor egresada de pediatría
UNIVERSIDAD DE CHILE
Chile, 2000
Distinción otorgada por obtener las mejores calificaciones durante la especialización en pediatría
Escala de predicción de infecciones postcirugía cardíaca en pediatría |
A Prospective Study to Assess the Pediatric Respiratory Syncytial Virus (RSV) Electronic Severity an Outcome Rating System (PRESORS) and Clinical Endpoints in Neonates, Infants, and Children >= 36 month of Age Hospitalized with RSV Infection |
Genetic and systemic biomarkers associated with severity of invasive fungal disease in children with cancer, fever and neutropenia=> A new insight |
CLINICAL SEVERITY AND SPECIFIC GENE EXPRESSION PROFILE IN RESPIRATORY VIRAL INFECTIONS IN CHILDREN WITH CANCER, FEVER AND NEUTROPENIA=> A STEP FORWARD. |
A PHASE II/III STUDY OF CHIMERIC MONOCLONAL ANTIBODIES TO SHIGA TOXINS 1 (caStx1) AND (caStx2) ADMINISTERED CONCOMITANTLY TO CHILDREN WITH SHIGA TOXIN-PRODUCING BACTERIAL (STPB) INFECTION AND BLOODY DIARRHEA |
A PHASE 2B/3, MULTI-CENTER, OBSERVED-BLIND CONTROLLED STUDY OF THE SAFETY, TOLERABILITY AND INMUNOGENICITY OF NOVARTIS MENINGOCOCCAL B RECOMBINANT VACCINE ADMINISTERED TO HAELTHY ADOLESCENTS AGED 11-17 YEARS ACCORDING TO DIFFERENT VACCINATION SCHEDULES |
SAFETY STUDY OF MENACTRA (MENINGOCOCCAL (GROUPS A, C , Y AND W-135) POLYSACCHARIDE DIPHTERIA TOXOID CONJUGATE VACCINE) WHEN ADMINISTERED WITH OTHER PEDIATRICS VACCINES TO HEALTHY TODDLERS |
A PHASE 2 OBSERVER-BLIND FOLLOW-UP STUDY WITH TWO GROUPS TO ASSES THE REACTOGENICITY AND INMUNOGENICITY OF GSK 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (GSK 102485OA) WHEN EITHER GIVEN AS A BOOSTER DOSE IN PRIMED CHILDREN OR AS TWO-DOSE CATCH UP INMUNIZAT |
A PHASE II RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE A SINGLE INTRAVENOUS DOSE OF MOTAVIZUMAB (MEDI-524), A HUMANIZED ENHANCED POTENCY MONOCLONAL ANTIBODY AGAINST RESPIRATORY SYNCYTIAL VIRUS (SRV), FOR THE TREATMENT OF CHILDREN HOSPIT |
A PROSPECTIVE, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, COMPARATIVE STUDY TO EVALUATE THE SAFETY, LOCAL TOLERABILITY, AND CLINICAL OUTCOME OF ERTAPENEM SODIUM (MK-0826) vs. CEFTRIAXONE SODIUM IN PEDIATRIC PATIENTS WITH COMPLICATED URINARY TRACT INFECTION, |
AN OPEL-LABEL, INTRAVENOUS STUDY TO EVALUATE THE CEREBROSPINAL FLUID CONCENTRATION PROFILES OF MK-0826 IN PATIENTS AGED 3 MONTH THROUGH 17 AÑOS |